| 摘要 |
<P>PROBLEM TO BE SOLVED: To clarify a novel mechanism of insulin resistance or liver diseases, or to clarify an effect of administration of retinoid to a living body. <P>SOLUTION: A drug containing retinoid and given to a liver disease patient of a non-genetically modified animal serves as at least one selected from the group consisting of an insulin resistance improvement agent, a weight gain controlling agent, a weight reducing agent, a liver weight reducing agent, a visceral fat increase inhibiting agent, a food intake inhibiting agent, a calorie intake inhibiting agent, a blood AST reducing agent, a blood ALT reducing agent, an adiposis inhibiting agent for liver tissues, a free fatty acid reducing agent for liver tissues, a triglyceride reducing agent for liver tissues, a total cholesterol reducing agent for liver tissues, a blood glucose level reducing agent, a blood insulin level reducing agent, an abnormal glucose tolerance improving agent, an insulin sensitivity improving agent, a leptin resistance improving agent, a blood leptin level reducing agent, a blood free fatty acid reducing agent, and adipocytokine (bad in blood) reducing agent. <P>COPYRIGHT: (C)2012,JPO&INPIT |
